TNFRSF10B and pancreatic neoplasm: Conatumumab (AMG-655), a fully human agonistic monoclonal antibody (IgG1) directed against TRAIL-R2, was shown to induce apoptosis in vitro and in pancreatic cancer xenograft models in vivo.